| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Johns Hopkins Oncology Center, Baltimore, Maryland 21231 [J. G., J. T. I.], and Graduate Program of Cellular and Molecular Medicine [J. G.] and James Buchanan Brady Urology Institute, Department of Urology [J. T. I.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231
Whether androgen regulates the proliferation and survival of androgen-responsive prostate cancer cells directly or indirectly via a paracrine pathway initiated in androgen receptor (AR)-expressing stromal cells is unknown. To resolve this issue, female mice heterozygous for the testicular feminized male loss of function mutation in their X-linked AR genes were cross-bred to T cell-defective homozygous male nude mice. Using a PCR-based restriction enzyme digestion method, the resulting AR/tfm, Nu/nu F1 hybrid females were identified and back-crossed to homozygous male nude mice to produce AR-null male nude mice lacking both AR and T-cell function. Androgen-responsive PC-82 human prostate cancers were xenografted into these AR-null versus AR-wild-type male nude mice. In both backgrounds, the cancer cells did not grow in nonandrogenized hosts. In contrast, PC-82 prostate cancer cells grew with identical characteristics (i.e., take rate, morphology, PSA expression, growth rate, and percentage of cell proliferating or dying) in androgenized hosts of both backgrounds. Likewise, in both backgrounds, androgen ablation of mice bearing growing PC-82 cancers resulted in the inhibition of proliferation and activation of programmed (apoptotic) cell death of the cancer cells. These results demonstrate that both the androgen-stimulated proliferation and the suppression of programmed cell death of PC-82 human prostate cancer cells are initiated by the AR pathway directly within these cancer cells themselves and do not involve initiation by AR-expressing stromal cells in a paracrine manner.
1 To whom requests for reprints should be addressed, at Johns Hopkins Oncology Center, 422 North Bond Street, Baltimore, MD 21231.
Received 2/ 6/98. Accepted 6/ 3/98.
This article has been cited by other articles:
|
|
 |
|
  J. H. Suh, M. Shong, H.-S. Choi, and K. Lee CR6-Interacting Factor 1 Represses the Transactivation of Androgen Receptor by Direct Interaction Mol. Endocrinol., January 1, 2008; 22(1): 33 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Watson, K. Ellwood-Yen, J. C. King, J. Wongvipat, M. M. LeBeau, and C. L. Sawyers Context-Dependent Hormone-Refractory Progression Revealed through Characterization of a Novel Murine Prostate Cancer Cell Line Cancer Res., December 15, 2005; 65(24): 11565 - 11571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fu, M. Rao, C. Wang, T. Sakamaki, J. Wang, D. Di Vizio, X. Zhang, C. Albanese, S. Balk, C. Chang, et al. Acetylation of Androgen Receptor Enhances Coactivator Binding and Promotes Prostate Cancer Cell Growth Mol. Cell. Biol., December 1, 2003; 23(23): 8563 - 8575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. V. Litvinov, A. M. De Marzo, and J. T. Isaacs Is the Achilles' Heel for Prostate Cancer Therapy a Gain of Function in Androgen Receptor Signaling? J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 2972 - 2982. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mareel and A. Leroy Clinical, Cellular, and Molecular Aspects of Cancer Invasion Physiol Rev, April 1, 2003; 83(2): 337 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Weeraratna, S. L. Dalrymple, J. C. Lamb, S. R. Denmeade, S. Miknyoczki, C. A. Dionne, and J. T. Isaacs Pan-trk Inhibition Decreases Metastasis and Enhances Host Survival in Experimental Models as a Result of Its Selective Induction of Apoptosis of Prostate Cancer Cells Clin. Cancer Res., August 1, 2001; 7(8): 2237 - 2245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gao, J. T. Arnold, and J. T. Isaacs Conversion from a Paracrine to an Autocrine Mechanism of Androgen-stimulated Growth during Malignant Transformation of Prostatic Epithelial Cells Cancer Res., July 1, 2001; 61(13): 5038 - 5044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Isaacs Apoptosis: Translating Theory to Therapy for Prostate Cancer J Natl Cancer Inst, September 6, 2000; 92(17): 1367 - 1369. [Full Text] [PDF]
|
|
|
|
|
|
J.-T. Dong, C. Chen, B. G. Stultz, J. T. Isaacs, and H. F. Frierson Jr. Deletion at 13q21 Is Associated with Aggressive Prostate Cancers Cancer Res., July 1, 2000; 60(14): 3880 - 3883. [Abstract] [Full Text]
|
|
|
|
|
|
N. Craft, C. Chhor, C. Tran, A. Belldegrun, J. DeKernion, O. N. Witte, J. Said, R. E. Reiter, and C. L. Sawyers Evidence for Clonal Outgrowth of Androgen-independent Prostate Cancer Cells from Androgen-dependent Tumors through a Two-Step Process Cancer Res., October 1, 1999; 59(19): 5030 - 5036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Carson, G. Kulik, and M. J. Weber Antiapoptotic Signaling in LNCaP Prostate Cancer Cells: A Survival Signaling Pathway Independent of Phosphatidylinositol 3'-Kinase and Akt/Protein Kinase B Cancer Res., April 1, 1999; 59(7): 1449 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Petre, Y. B. Wetherill, M. Danielsen, and K. E. Knudsen Cyclin D1: Mechanism and Consequence of Androgen Receptor Co-repressor Activity J. Biol. Chem., January 11, 2002; 277(3): 2207 - 2215. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
